You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The assay uses the propensity of pathogenic tau protein filaments to self-assemble and could enable more accurate and earlier detection of Alzheimer's.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
The company is also looking to expand the use of its FDA-approved ClonoSeq assay, which has US FDA approval for MRD detection in acute lymphocytic leukemia and multiple myeloma.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
The solutions being developed will leverage AI from labs globally and will accelerate the number of new test algorithms available to the lab diagnostics market.
At JP Morgan, Qiagen CEO Peer Schatz discussed a new digital PCR system and handheld reader for TB testing; Qiagen's acquisition of N-of-One; and its new sample prep system.
In a recent study, researchers found that a PSA SNP variant affected protein stability, activity, and glycosylation, and could impact clinical measurements.
The combined debt and equity financing for the Washington state allergy lab comes as demand for food-related allergy testing is growing.
Siemens Healthineers CEO Bernd Montag talked about the positive impact the firm's Attelica system is having on its revenues, while Bruker discussed plans for the BioTyper platform and assays in the pipeline.
The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.